The emerging role of transcription factor FOXP3 in thyroid cancer

Gong, Zhongqin; Hao, Jia; Xue, Lingbin; Li, Dongcai; Zeng, Xianhai; Wei, Minghui; Liu, Zhimin; Tong, Michael C. F.; Chen, George G

doi:10.1007/s11154-021-09684-8

Cited by 9 publications

(9 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have shown that the proportion of Tregs in the peripheral blood is significantly increased in patients with malignant tumors ( 16 – 19 ). The same trend was observed in response to tumor infiltration and the microenvironment of several cancers ( 20 , 21 ), including thyroid cancer ( 8 , 22 , 23 ).…”

Section: Discussionsupporting

confidence: 66%

Dynamic Immune Function Changes Before and After the First Radioactive Iodine Therapy After Total Resection of Differentiated Thyroid Carcinoma

Shi

Zhang²,

Fan³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

The effects of total thyroidectomy or radioactive iodine therapy on immune activation and suppression of the tumor microenvironment remain unknown. We aimed to investigate the effects of these treatments on the immune function in patients with differentiated thyroid carcinoma (DTC). Our cohort included 45 patients with DTC treated with total thyroidectomy and radioactive iodine therapy (RAIT). Immune function tests were performed by flow cytometry at 0, 30, and 90 days post-RAIT. Both the percentage and absolute number of circulating regulatory T cells were significantly lower in the postoperative DTC compared to the healthy controls. Notably, the absolute number of multiple lymphocyte subgroups significantly decreased at 30 days post-RAIT compared to those pre-RAIT. The absolute counts of these lymphocytes were recovered at 90 days post-RAIT, but not at pre-RAIT levels. Additionally, the Th17 cell percentage before RAIT was positively correlated with thyroglobulin (Tg) levels after RAIT. The tumor burden might contribute to increased levels of circulating Tregs. In conclusion, RAIT caused transient radiation damage in patients with DTC and the percentage of Th17 cells before RAIT could be a significant predictor of poor prognosis in patients with DTC.

show abstract

Section: Discussionsupporting

confidence: 66%

Dynamic Immune Function Changes Before and After the First Radioactive Iodine Therapy After Total Resection of Differentiated Thyroid Carcinoma

Shi

Zhang²,

Fan³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Many studies have shown that there is generally a significant increase in the number of regulatory T cells (Tregs) in tumor tissue, and the close interaction between them and effector T cells exhibited an immunosuppressive and immune incompetent characteristic [ 46 ]. This kind of Tregs is indicated by a presence of Foxp3 [ 47 ]. Therefore, analyzing Foxp3 staining in both primary tumor and distant tumor sections could reveal treatment outcome.…”

Section: Resultsmentioning

confidence: 99%

Albumin-based nanosystem for dual-modality imaging-guided chem-phototherapy against immune-cold triple-negative breast cancer

Peng,

Zeng,

Cai

et al. 2023

Regenerative Biomaterials

View full text Add to dashboard Cite

Triple-negative breast cancer is a highly aggressive and metastatic tumor; diagnosing it in the early stages is still difficult, and the prognosis for conventional radio-chemotherapy and immunotreatment is not promising due to cancer’s immunosuppressive microenvironment. The utilization of protein-based nanosystem has proven to be effective in delivering agents with limited adverse effects, yet the combination of diagnosis and treatment remains a difficult challenge. This research took advantage of natural albumin and organic molecules to construct a self-assemble core-shell nanostructure combining with superparamagnetic iron oxide nanocrystals and heptamethine cyanine dye IR780 through non-covalent interactions. This nanocomposite successfully decreased the transverse relaxation time of the magnetic resonance hydrogen nucleus, resulting in outstanding T2 imaging, as well as emitting near-infrared II fluorescence, thereby the resulting dual-modality imaging tool was applied to improve diagnostic competency. It is noteworthy that the nanocomposites exhibited impressive enzyme-like catalytic and photothermal capabilities, resulting in a successful activation of the immune system to efficiently suppress distant metastatic lesions in vivo. Consequently, this nanodrug-based therapy could be an advantageous asset in reinforcing the immune system and hindering the growth and reappearance of the immune-cold breast cancer.

show abstract

“…Anti‐PD‐1 antibody plus lenvatinib therapy showed less effectiveness against unresectable hepatocellular carcinomas and LNM than against macrovascular tumor thrombi or lung metastases 17,18 . A similar result might be expected in thyroid cancer with LN involvement 19 . Furthermore, advanced gastric cancer with LNM showed a favorable survival rate under nivolumab treatment 20 .…”

Section: Discussionmentioning

confidence: 67%

“… 17 , 18 A similar result might be expected in thyroid cancer with LN involvement. 19 Furthermore, advanced gastric cancer with LNM showed a favorable survival rate under nivolumab treatment. 20 These distinct reactions to IO drugs could be due to biological differences among carcinomas and/or the immune status of infiltrating T cells in LNs.…”

Section: Discussionmentioning

confidence: 99%

Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma

et al. 2023

View full text Add to dashboard Cite

BackgroundNivolumab plus ipilimumab (NIVO+IPI) is the first‐line treatment for patients with metastatic renal cell carcinoma (mRCC). Approximately 40% of patients achieve a durable response; however, 20% develop primary resistant disease (PRD) to NIVO+IPI, about which little is known in patients with mRCC. Therefore, this investigation aimed to evaluate the clinical implication of PRD in patients with mRCC to select better candidates in whom NIVO+IPI can be initiated as first‐line therapy.MethodsThis multi‐institutional retrospective cohort study used data collected between August 2015 and January 2023. In total, 120 patients with mRCC treated with NIVO+IPI were eligible. Associations between immune‐related adverse events and progression‐free survival, overall survival (OS), and objective response rate were analyzed. The relationship between other clinical factors and outcomes was also evaluated.ResultsThe median observation period was 16 months (interquartile range, 5–27). The median age at NIVO+IPI initiation was 68 years in the male‐dominant population (n = 86, 71.7%), and most patients had clear cell histology (n = 104, 86.7%). PRD was recorded in 26 (23.4%) of 111 investigated patients during NIVO+IPI therapy. Patients who experienced PRD showed worse OS (hazard ratio: 4.525, 95% confidence interval [CI]: 2.315–8.850, p < 0.001). Multivariable analysis showed that lymph node metastasis (LNM) (odds ratio: 4.274, 95% CI: 1.075–16.949, p = 0.039) was an independent risk factor for PRD.ConclusionsPRD was strongly correlated with worse survival rates. LNM was independently associated with PRD in patients with mRCC receiving NIVO+IPI as first‐line therapy and might indicate that a candidate will not benefit from NIVO+IPI.

show abstract

The emerging role of transcription factor FOXP3 in thyroid cancer

Cited by 9 publications

References 71 publications

Dynamic Immune Function Changes Before and After the First Radioactive Iodine Therapy After Total Resection of Differentiated Thyroid Carcinoma

Dynamic Immune Function Changes Before and After the First Radioactive Iodine Therapy After Total Resection of Differentiated Thyroid Carcinoma

Albumin-based nanosystem for dual-modality imaging-guided chem-phototherapy against immune-cold triple-negative breast cancer

Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma

Contact Info

Product

Resources

About